Q-omics provides the consensus-scored TRMT2B-AS1 profile across patient tissues and cancer cell-line models. TRMT2B-AS1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TRMT2B-AS1 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, TRMT2B-AS1 RNA expression shows 12,278 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight UVM, KICH, and LAML as cancer lineages where TRMT2B-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRMT2B-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRMT2B-AS1 survival associations across molecular data types. TRMT2B-AS1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRMT2B-AS1 RNA expression–survival associations across cancer types. High TRMT2B-AS1 expression shows unfavorable associations in UVM and CESC, but favorable associations in ACC, GBM, KIRP and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TRMT2B-AS1 RNA expression.
This table summarizes TRMT2B-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TRMT2B-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRMT2B-AS1 shows higher tumor expression in KICH, STAD, COAD, BLCA, KIRP and THCA. The KICH box plot shows higher TRMT2B-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.300, t-test p = .002).
This table shows molecular features associated with TRMT2B-AS1 in patient tissues and cancer cell lines. In patient samples, TRMT2B-AS1 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
